Contrave Tablet, Extended Release
Product Images NDC 51267-890

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Contrave (NDC 51267-890). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nalpropion Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Table 1 (Contrave Er 01)

Table 1 (Contrave Er 01)
FDA Label Image

Naltrexone Hydrochloride Chemical Structure (Contrave Er 02)

Naltrexone Hydrochloride Chemical Structure (Contrave Er 02)
FDA Label Image

Bupropion Hydrochloride Chemical Structure (Contrave Er 03)

Bupropion Hydrochloride Chemical Structure (Contrave Er 03)
FDA Label Image

Figure 1 (Contrave Er 04)

Figure 1 (Contrave Er 04)
This appears to be a graph showing weight change from baseline over time (in weeks) for a group of participants taking a weight loss medication called CONTRAVE32/360 and a comparison group taking a placebo. The graph shows data up to 56 weeks and is divided into intervals of 4 weeks. However, the output is incomplete and some characters are missing, resulting in unclear information.*
FDA Label Image

Figure 1 (Contrave Er 05)

Figure 1 (Contrave Er 05)
The text seems to be a chart showing weight change from baseline over a period of 52 weeks. Two groups are being compared: a group taking Pacebo (probably placebo) and another group taking Contrave32360. The units for weight change are expressed as a percentage. Information about the size and characteristics of the groups is not available, and the meaning of the abbreviations ITT-LOCF and B3 is unclear.*
FDA Label Image

Figure 1 (Contrave Er 06)

Figure 1 (Contrave Er 06)
FDA Label Image

8 mg/90 mg 120-count Bottle Label (Contrave Er 07)

8 mg/90 mg 120-count Bottle Label (Contrave Er 07)
The text has information related to a medicine named "Contrave". It comes in a packaging of 120 extended-release tablets and contains 8mg of naloxone HCI and 90mg of bupropion HCI. Tablets should not be cut or crushed. The medicine is registered with the trademark of Nalpropion Pharmaceuticals LLC and distributed by Currax Pharmaceuticals LLC. Other details include the warning to not accept if the seal is broken or missing.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.